Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.125 USD | -2.07% | +0.94% | -68.93% |
Apr. 29 | Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment | MT |
Apr. 18 | Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.93% | 57.28M | |
-4.24% | 86.85B | |
+2.76% | 40.16B | |
-16.52% | 31.28B | |
+57.86% | 25.27B | |
-15.28% | 15.33B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.89% | 8.83B | |
-10.53% | 7.94B |
- Stock Market
- Equities
- IMMX Stock
- News Immix Biopharma, Inc.
- Immix Says Median Progression-Free Survival Not Yet Reached in Trial of IMX-110 Plus Tislelizumab in Colorectal Cancer